SAN DIEGO, Oct. 1, 2007 (PRIME NEWSWIRE) -- Sagient Research Systems, a leading publisher of independent research for the financial services and institutional investment communities, today announced the launch of its new service CatalystTracker. CatalystTracker provides investors the most efficient method to track and analyze upcoming volatility events which could immediately change the value of public companies. These volatility events (Catalysts) are constantly added and updated by Sagient's in-house analyst team and presented to clients online in an easy to use, searchable, and customizable platform. The initial coverage area is the healthcare sector, which includes biotech, major pharmaceuticals, medical devices, diagnostics, and specialty/generic pharmaceuticals.
CatalystTracker is the third proprietary institutional research service from Sagient Research. Sagient Research revolutionized the PIPE market (Private Investment in Public Equity) in 1999 with the launch of PlacementTracker and has maintained its position as the leading provider of research, data, and analytics covering that market for eight years. In 2003, the company launched BioMedTracker which has won accolades from investment funds, investment banks, and biotech and pharmaceutical companies for its unique and comprehensive coverage of developmental stage drugs and the public companies that own them. In launching CatalystTracker, Sagient Research has harnessed the same commitment to proprietary data, best-of-breed online interfaces, and world class client services that have made PlacementTracker and BioMedTracker phenomenal successes in the institutional research market.
Accompanying the launch of CatalystTracker, Sagient released its ground-breaking research report, The Catalyst Impact Study. For the first time, this report identifies the catalysts that have the most dramatic effect on the price of a company's stock and quantifies the historical movements around the date the catalyst occurred. The study found that Data Monitoring Board Analyses for public biotech companies create the largest average absolute change in stock prices, followed by PDUFA dates, and top-line trial data results.
CatalystTracker provides the institutional investing and trading communities a way to capitalize on these upcoming events and to manage event risk in their portfolios.
There are several large catalysts due out before the end of the year which could have a dramatic effect on the long-term and short-term price of the companies' stocks. A sample of such catalysts includes the following:
Expected
Company Product Status Date Range Catalyst Type
Medtronic, Inc. Endeavor PMA 10/10/2007 Regulatory -
FDA Advisory
Panel Meeting
BioMarin Kuvan NDA 11/25/2007 Regulatory -
Pharmaceutical, PDUFA/Approval
Inc. Decision
(U.S.)
Amylin Exenatide II/III Now - Trial Data -
Pharmaceuticals, LAR 11/30/2007 Top-Line
Inc. Results
Commenting on the launch of CatalystTracker, Robert F. Kyle, executive vice president of Sagient Research stated, "The timing of events like releases of clinical trial data or FDA approval decision announcements is constantly changing. Information about these catalysts comes from a variety of sources that are often difficult to find. Before CatalystTracker there was no comprehensive way to track all of this information in one place. Since these events will determine the future value of a product that a company is developing, they have a direct and significant impact on the price of a company's stock. Having a comprehensive, up-to-date, easily searchable central repository of this data creates an enormous opportunity and advantage for traders and investors. Using CatalystTracker and the Catalyst Impact Study to determine the timing and magnitude of these upcoming events is a powerful tool that no one investing in today's market should be without."
CatalystTracker can be accessed online with a paid subscription via www.CatalystTracker.com.
To arrange for a demonstration of CatalystTracker or to obtain a copy of The Catalyst Impact Study, please send an inquiry to CatalystSubscribe@sagientresearch.com.
About Sagient Research Systems
Sagient Research Systems is a publisher of independent research. We develop, produce, and sell proprietary research products to mutual funds, hedge funds, and investment banks. Our business strategy is to continue to leverage our development, technology, and marketing expertise to solidify our position as a leading provider of independent research to the financial services and institutional investment communities. In September 2007, Sagient Research was named to the inaugural Inc. 5000 list of fastest growing companies. For more information, please visit the Sagient Research Systems website at www.sagientresearch.com.